NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

David Snodin, PhD, MChemA, MSc, FRSC, FTOPRA

Practice Area Focus

  • Drugs
  • Toxicology
  • Development Strategy
  • Regulatory Strategy (EU)


Dr. David Snodin joined NDA Partners in 2013. He is an expert in regulatory toxicology with more than 35 years of experience at MHRA and in the Industry.

Dr. Snodin was an Expert Preclinical Assessor at the UK Medicines and Healthcare products Regulatory Agency (MHRA) and UK representative on CHMP Safety Working Party, prior to his position as Vice President of Nonclinical at PAREXEL International Drug Development Consulting. Initially, his career was in the food industry where he specialized in toxicology, environmental, and regulatory affairs on food and pharmaceutical ingredients and served as Safety and Regulatory Affairs Manager with Tate & Lyle.

Dr. Snodin’s expertise is in toxicological impurity qualification, environmental risk assessment, preparation of non-clinical overviews and response to agency questions, safety assessment of e-cigarettes, and determination of PDEs (Permitted Daily Exposures) as a metric for health-based exposure limits.